Related references
Note: Only part of the references are listed.Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance
Jinseong Kim et al.
JOURNAL OF CONTROLLED RELEASE (2021)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy
Qianmei Yang et al.
THERANOSTICS (2020)
Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy
Xiaopin Duan et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
Synergistic triple-combination therapy with hyaluronic acid-shelled PPy/CPT nanoparticles results in tumor regression and prevents tumor recurrence and metastasis in 4T1 breast cancer
Wei Sun et al.
BIOMATERIALS (2019)
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
K. M. Heinhuis et al.
ANNALS OF ONCOLOGY (2019)
The potentiated checkpoint blockade immunotherapy by ROS-responsive nanocarrier-mediated cascade chemo-photodynamic therapy
Liqin Hu et al.
BIOMATERIALS (2019)
Visible light-induced apoptosis activatable nanoparticles of photosensitizer-DEVD-anticancer drug conjugate for targeted cancer therapy
Wooram Um et al.
BIOMATERIALS (2019)
Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy
Man Kyu Shim et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy
Seungho Lim et al.
THERANOSTICS (2019)
Structural Polymorphism in a Self-Assembled Tri-Aromatic Peptide System
Noam Brown et al.
ACS NANO (2018)
Combinational strategy for high-performance cancer chemotherapy
Si-Yong Qin et al.
BIOMATERIALS (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Pembrolizumab (pembro) plus chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Jennifer I. Hare et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Cathepsin B-Specific Metabolic Precursor for In Vivo Tumor-Specific Fluorescence Imaging
Man Kyu Shim et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy
Xiao Zhao et al.
BIOMATERIALS (2016)
Doxorubicin-Induced Systemic Inflammation Is Driven by Upregulation of Toll-Like Receptor TLR4 and Endotoxin Leakage
Lintao Wang et al.
CANCER RESEARCH (2016)
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
Dimitrios Mathios et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Analysis of nanoparticle delivery to tumours
Stefan Wilhelm et al.
NATURE REVIEWS MATERIALS (2016)
Self-Assembly of Phenylalanine-Based Molecules
Helen W. German et al.
JOURNAL OF PHYSICAL CHEMISTRY A (2015)
TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells
Hongliang Fang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2014)
Different endocytotic uptake mechanisms for nanoparticles in epithelial cells and macrophages
Dagmar A. Kuhn et al.
BEILSTEIN JOURNAL OF NANOTECHNOLOGY (2014)
Cathepsin B as a cancer target
Christopher S. Gondi et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)
Yan-Jun Zhong et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Peptide-Mediated Liposomal Doxorubicin Enhances Drug Delivery Efficiency and Therapeutic Efficacy in Animal Models
De-Kuan Chang et al.
PLOS ONE (2013)
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
Jun Fang et al.
ADVANCED DRUG DELIVERY REVIEWS (2011)
Biodegradable star HPMA polymer conjugates of doxorubicin for passive tumor targeting
Tomas Etrych et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Adriana Albini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice
Alexander Riad et al.
EUROPEAN JOURNAL OF HEART FAILURE (2008)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Anticancer carrier-linked prodrugs in clinical trials
Felix Kratz et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
A review of poloxamer 407 pharmaceutical and pharmacological characteristics
Gilles Dumortier et al.
PHARMACEUTICAL RESEARCH (2006)
Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells
A David et al.
EUROPEAN JOURNAL OF CANCER (2004)
The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy
VM Garsky et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice
JG Shiah et al.
EUROPEAN JOURNAL OF CANCER (2001)
Share Paper
